These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 34475526)

  • 21. [Expression and clinical significance of Mucin and E-cadherin in colorectal tumors].
    Yu XW; Rong W; Xu FL; Xu GY; Sun YR; Feng MY
    Ai Zheng; 2007 Nov; 26(11):1204-10. PubMed ID: 17991319
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Significance of mucin expression in pancreatobiliary neoplasms.
    Yonezawa S; Higashi M; Yamada N; Yokoyama S; Goto M
    J Hepatobiliary Pancreat Sci; 2010 Mar; 17(2):108-24. PubMed ID: 19787286
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression of mucins (MUC1, MUC2, MUC3, MUC4, MUC5AC and MUC6) and their prognostic significance in human breast cancer.
    Rakha EA; Boyce RW; Abd El-Rehim D; Kurien T; Green AR; Paish EC; Robertson JF; Ellis IO
    Mod Pathol; 2005 Oct; 18(10):1295-304. PubMed ID: 15976813
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinicopathological characteristics, microsatellite instability, and expression of mucin core proteins and p53 in colorectal mucinous adenocarcinomas in relation to location.
    Park SY; Lee HS; Choe G; Chung JH; Kim WH
    Virchows Arch; 2006 Jul; 449(1):40-7. PubMed ID: 16645863
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The prognostic impact of consensus molecular subtypes (CMS) and its predictive effects for bevacizumab benefit in metastatic colorectal cancer: molecular analysis of the AGITG MAX clinical trial.
    Mooi JK; Wirapati P; Asher R; Lee CK; Savas P; Price TJ; Townsend A; Hardingham J; Buchanan D; Williams D; Tejpar S; Mariadason JM; Tebbutt NC
    Ann Oncol; 2018 Nov; 29(11):2240-2246. PubMed ID: 30247524
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mucin core protein expression in colorectal cancers with high levels of microsatellite instability indicates a novel pathway of morphogenesis.
    Biemer-Hüttmann AE; Walsh MD; McGuckin MA; Simms LA; Young J; Leggett BA; Jass JR
    Clin Cancer Res; 2000 May; 6(5):1909-16. PubMed ID: 10815915
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical and molecular characterization of early-onset colorectal cancer.
    Willauer AN; Liu Y; Pereira AAL; Lam M; Morris JS; Raghav KPS; Morris VK; Menter D; Broaddus R; Meric-Bernstam F; Hayes-Jordan A; Huh W; Overman MJ; Kopetz S; Loree JM
    Cancer; 2019 Jun; 125(12):2002-2010. PubMed ID: 30854646
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Image-based consensus molecular subtype (imCMS) classification of colorectal cancer using deep learning.
    Sirinukunwattana K; Domingo E; Richman SD; Redmond KL; Blake A; Verrill C; Leedham SJ; Chatzipli A; Hardy C; Whalley CM; Wu CH; Beggs AD; McDermott U; Dunne PD; Meade A; Walker SM; Murray GI; Samuel L; Seymour M; Tomlinson I; Quirke P; Maughan T; Rittscher J; Koelzer VH;
    Gut; 2021 Mar; 70(3):544-554. PubMed ID: 32690604
    [TBL] [Abstract][Full Text] [Related]  

  • 29. KRAS Mutation and Consensus Molecular Subtypes 2 and 3 Are Independently Associated with Reduced Immune Infiltration and Reactivity in Colorectal Cancer.
    Lal N; White BS; Goussous G; Pickles O; Mason MJ; Beggs AD; Taniere P; Willcox BE; Guinney J; Middleton GW
    Clin Cancer Res; 2018 Jan; 24(1):224-233. PubMed ID: 29061646
    [No Abstract]   [Full Text] [Related]  

  • 30. The Balance Between Cytotoxic T-cell Lymphocytes and Immune Checkpoint Expression in the Prognosis of Colon Tumors.
    Marisa L; Svrcek M; Collura A; Becht E; Cervera P; Wanherdrick K; Buhard O; Goloudina A; Jonchère V; Selves J; Milano G; Guenot D; Cohen R; Colas C; Laurent-Puig P; Olschwang S; Lefèvre JH; Parc Y; Boige V; Lepage C; André T; Fléjou JF; Dérangère V; Ghiringhelli F; de Reynies A; Duval A
    J Natl Cancer Inst; 2018 Jan; 110(1):. PubMed ID: 28922790
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular Subtypes.
    Loree JM; Pereira AAL; Lam M; Willauer AN; Raghav K; Dasari A; Morris VK; Advani S; Menter DG; Eng C; Shaw K; Broaddus R; Routbort MJ; Liu Y; Morris JS; Luthra R; Meric-Bernstam F; Overman MJ; Maru D; Kopetz S
    Clin Cancer Res; 2018 Mar; 24(5):1062-1072. PubMed ID: 29180604
    [No Abstract]   [Full Text] [Related]  

  • 32. Colorectal Cancer Consensus Molecular Subtypes Translated to Preclinical Models Uncover Potentially Targetable Cancer Cell Dependencies.
    Sveen A; Bruun J; Eide PW; Eilertsen IA; Ramirez L; Murumägi A; Arjama M; Danielsen SA; Kryeziu K; Elez E; Tabernero J; Guinney J; Palmer HG; Nesbakken A; Kallioniemi O; Dienstmann R; Lothe RA
    Clin Cancer Res; 2018 Feb; 24(4):794-806. PubMed ID: 29242316
    [No Abstract]   [Full Text] [Related]  

  • 33. Molecular and clinicopathological differences between depressed and protruded T2 colorectal cancer.
    Mochizuki K; Kudo SE; Kato K; Kudo K; Ogawa Y; Kouyama Y; Takashina Y; Ichimasa K; Tobo T; Toshima T; Hisamatsu Y; Yonemura Y; Masuda T; Miyachi H; Ishida F; Nemoto T; Mimori K
    PLoS One; 2022; 17(10):e0273566. PubMed ID: 36264865
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Functional proteomics of colon cancer Consensus Molecular Subtypes.
    Feliu J; Gámez-Pozo A; Martínez-Pérez D; Pérez-Wert P; Matamala-Luengo D; Viñal D; Kunz L; López-Vacas R; Dittmann A; Rodríguez-Salas N; Custodio A; Fresno Vara JÁ; Trilla-Fuertes L
    Br J Cancer; 2024 Jun; 130(10):1670-1678. PubMed ID: 38486123
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Classification of patients with metastatic colorectal cancer into consensus molecular subtypes into real-world: A pilot study.
    González-Montero J; Burotto M; Valenzuela G; Mateluna D; Buen-Abad F; Toro J; Barajas O; Marcelain K
    World J Clin Oncol; 2023 Oct; 14(10):409-419. PubMed ID: 37970108
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The serrated neoplasia pathway of colorectal tumors: Identification of MUC5AC hypomethylation as an early marker of polyps with malignant potential.
    Renaud F; Mariette C; Vincent A; Wacrenier A; Maunoury V; Leclerc J; Coppin L; Crépin M; Van Seuningen I; Leteurtre E; Buisine MP
    Int J Cancer; 2016 Mar; 138(6):1472-81. PubMed ID: 26476272
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MUC5B expression in gastric carcinoma: relationship with clinico-pathological parameters and with expression of mucins MUC1, MUC2, MUC5AC and MUC6.
    Pinto-de-Sousa J; Reis CA; David L; Pimenta A; Cardoso-de-Oliveira M
    Virchows Arch; 2004 Mar; 444(3):224-30. PubMed ID: 14758553
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunohistochemistry-Based Consensus Molecular Subtypes as a Prognostic and Predictive Biomarker for Adjuvant Chemotherapy in Patients with Stage II Colorectal Cancer.
    Li Y; Yao Q; Zhang L; Mo S; Cai S; Huang D; Peng J
    Oncologist; 2020 Dec; 25(12):e1968-e1979. PubMed ID: 32926498
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression of membrane-bound mucins (MUC1 and MUC4) and secreted mucins (MUC2, MUC5AC, MUC5B, MUC6 and MUC7) in mucoepidermoid carcinomas of salivary glands.
    Alos L; Lujan B; Castillo M; Nadal A; Carreras M; Caballero M; de Bolos C; Cardesa A
    Am J Surg Pathol; 2005 Jun; 29(6):806-13. PubMed ID: 15897748
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A next-generation sequencing-based strategy combining microsatellite instability and tumor mutation burden for comprehensive molecular diagnosis of advanced colorectal cancer.
    Xiao J; Li W; Huang Y; Huang M; Li S; Zhai X; Zhao J; Gao C; Xie W; Qin H; Cai S; Bai Y; Lan P; Zou Y
    BMC Cancer; 2021 Mar; 21(1):282. PubMed ID: 33726687
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.